# US 2021/0069294 A1 · Serum response factor regenerates senescent cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069294 A1
- Document ID: US20210069294A1
- Status: Published application
- Kind: A1
- Application number: 16/959,944
- Filed: 2018-12-31
- Published: 2021-03-11
- Earliest claimed: 2018-01-05
- Assignees: University of Houston System
- Applicants: University of Houston System
- Inventors: Robert J. SCHWARTZ; Dinakar IYER
- Web page: https://patentgrep.com/patent/US20210069294A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 15/86: Viral vectors
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C12N 2501/60: Transcription factors
- C12N 2506/1307: from adult fibroblasts
- C12N 2506/1315: from cardiomyocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Loss of cardiomyocytes underlies most causes of heart failure, and normal repair processes are inadequate to deal with extensive myocardial damage. The inventors have identified mutations of the N-terminus of serum respose factor (SRF)'s MADS box, termed STEMINs, that block cardiac differentiation, but also powerfully activate the stem cell marker genes Nanog and Octomer 4, as well as cyclins, which promotes adult myocyte replication. SRF Stemin mutations are not cardiac-specific, and also propel mammalian fibroblasts into a proliferative state. Thus, STEMINs may be useful for regeneration of all tissue and organ types, by activating partial pluripotency programs and enhancing repair by increased cell replication. Following withdrawal of STEMINs, the cells then return to normal cell identity.

## Claims

### Claim 1

A method of inducing cell de-differentiation comprising providing to a target cell a STEMIN polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein providing comprises delivering a STEMIN polypeptide to said target cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein said STEMIN polypeptide comprises a heterologous cell permeability peptide (CPP).

### Claim 4 (depends on 2)

The method of claim 2, wherein said target cell is a cardiomyocyte.

### Claim 5 (depends on 2)

The method of claim 2, wherein said target cell is not a cardiomyocyte.

### Claim 6 (depends on 5)

The method of claim 5, wherein said target cell is a fibroblast, an endothelial cell or a neuronal cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein providing comprises delivering a STEMIN expression cassette to said target cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein said expression cassette is comprised in a replicable vector.

### Claim 9 (depends on 8)

The method of claim 8, wherein said replicable vector is a viral vector.

### Claim 10 (depends on 9)

The method of claim 9, wherein said viral vector is adeno-associated virus (AAV), non-integrated lentivirus, adenoviral vector or retroviral vector.

### Claim 11 (depends on 8)

The method of claim 8, wherein said replicable vector is a non-viral vector.

### Claim 12 (depends on 11)

The method of claim 11, wherein said non-viral vector is disposed in a lipid delivery vehicle.

### Claim 13 (depends on 1)

The method of claim 1, wherein providing comprises delivering a STEMIN-encoding mRNA.

### Claim 14 (depends on 13)

The method of claim 13, wherein said STEMIN-encoding RNA is bound to a nanoparticle.

### Claim 15 (depends on 14)

The method of claim 14, wherein said STEMIN-encoding RNA comprise one or more modified nucleotides, such as 5-methycytidine-5′-triphosphate and/or pseudouridine-5′-triphosphate.

### Claim 16

A method of inducing cell de-differentiation in a subject comprising providing to a target cell in said subject a STEMIN polypeptide.

### Claim 17 (depends on 16)

The method of claim 16, wherein providing comprises delivering a STEMIN polypeptide to said target cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein said STEMIN polypeptide comprises a heterologous cell permeability peptide (CPP).

### Claim 19 (depends on 17)

The method of claim 17, wherein said target cell is a cardiomyocyte.

### Claim 20 (depends on 17)

The method of claim 17, wherein said target cell is not a cardiomyocyte.

### Claim 21 (depends on 20)

The method of claim 20, wherein said target cell is a fibroblast, an endothelial cell or a neuronal cell.

### Claim 22 (depends on 16)

The method of claim 16, wherein providing comprises delivering a STEMIN expression cassette to said target cell.

### Claim 23 (depends on 22)

The method of claim 22, wherein said expression cassette is comprised in a replicable vector.

### Claim 24 (depends on 23)

The method of claim 23, wherein said replicable vector is a viral vector.

### Claim 25 (depends on 24)

The method of claim 24, wherein said viral vector is adeno-associated virus (AAV), non-integrated lentivirus, adenoviral vector or retroviral vector.

### Claim 26 (depends on 23)

The method of claim 23, wherein said replicable vector is a non-viral vector.

### Claim 27 (depends on 26)

The method of claim 26, wherein said non-viral vector is disposed in a lipid delivery vehicle.

### Claim 28 (depends on 16)

The method of claim 16, wherein providing comprises delivering a STEMIN-encoding mRNA.

### Claim 29 (depends on 28)

The method of claim 28, wherein said STEMIN-encoding RNA is bound to a nanoparticle.

### Claim 30 (depends on 29)

The method of claim 29, wherein said STEMIN-encoding RNA comprise one or more modified nucleotides, such as 5-methycytidine-5′-triphosphate and/or pseudouridine-5′-triphosphate.

### Claim 31 (depends on 17)

The method of claim 17, wherein a STEMIN polypeptide is delivered 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 times.

### Claim 32 (depends on 22)

The method of claim 22, wherein a STEMIN expression construct is delivered 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 times.

### Claim 33 (depends on 16)

The method of claim 16, wherein a STEMIN-encoding RNA is delivered 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 times.

### Claim 34 (depends on 31)

The method of claim 31, wherein a STEMIN polypeptide is provided daily.

### Claim 35 (depends on 32)

The method of claim 32, wherein a STEMIN expression construct is provided daily.

### Claim 36 (depends on 33)

The method of claim 33, wherein a STEMIN-encoding RNA is provided daily.

### Claim 37 (depends on 16)

The method of claim 16, wherein said subject has suffered a myocardial infarction and said target cell is a cardiomyocyte.

### Claim 38 (depends on 16)

The method of claim 16, wherein said subject suffers from heart failure and said target cell is a cardiomyocyte.

### Claim 39 (depends on 16)

The method of claim 16, wherein said subject has suffered non-cardiac tissue damage and said target cell is a fibroblast, an endothelial cell or a neuronal cell.

### Claim 40 (depends on 16)

The method of claim 16, wherein said subject suffers from heart failure and said target cell is a cardiomyocyte.

### Claim 41

A method preventing or delaying development of cardiac hypertrophy or heart failure in a subject having suffered a myocardial infarct (MI) comprising providing to said subject a STEMIN polypeptide.

### Claim 42 (depends on 41)

The method of claim 41, further comprising administering to said subject a secondary anti-hypertrophic or heart failure therapy.

### Claim 43 (depends on 41)

The method of claim 41, wherein the secondary therapy is a PKD inhibitor, a beta blocker, an ionotrope, a diuretic, ACE-I, All antagonist, BNP, a Ca++-blocker, or an HDAC inhibitor.

### Claim 44 (depends on 41)

The method of claim 41, wherein preventing or delaying comprises preventing or delaying cardiac hypertrophy.

### Claim 45 (depends on 41)

The method of claim 41, wherein preventing or delaying comprises preventing or delaying one or more of decreased exercise capacity, decreased cardiac ejection volume, increased left ventricular end diastolic pressure, increased pulmonary capillary wedge pressure, decreased cardiac output or cardiac index, increased pulmonary artery pressures, increased left ventricular end systolic and diastolic dimensions, increased left and right ventricular wall stress, increased wall tension, decreased quality of life, and/or increased disease related morbidity or mortality.

### Claim 46 (depends on 41)

The method of claim 41, wherein STEMIN polypeptides proteins are administered to said subject.

### Claim 47 (depends on 41)

The method of claim 41, wherein STEMIN expression cassettes are administered to said subject.

### Claim 48 (depends on 41)

The method of claim 41, wherein STEMIN-encoding mRNAs are administered to said subject.

### Claim 49 (depends on 41)

The method of claim 41, further comprising administering an anti-inflammatory agent to said subject.

### Claim 50

A method of reducing a decrease in exercise tolerance of a subject having suffered a myocardial infarction comprising providing to said subject a STEMINs polypeptide.

### Claim 51

A method of reducing hospitalization of a subject having suffered a myocardial infarction comprising providing to said subject a STEMINs polypeptide.

### Claim 52

A method of improving quality of life of a subject having suffered a myocardial infarction comprising providing to said subject a STEMINs polypeptide.

### Claim 53

A method of decreasing morbidity of a subject having suffered a myocardial infarction comprising providing to said subject a STEMINs polypeptide.

### Claim 54

A method of decreasing mortality of a subject having suffered a myocardial infarction comprising providing to said subject a STEMINs polypeptide.

### Claim 55

A polypeptide comprising at least 22 residues of the sequence SGAKPGKKTRGRVKIKMEFIDNKLRRYTTFSKRKTGIMKKAYELSTLT (SEQ ID NO: 1) and a mutation or mutations selected from an insertion, deletions or substitution in region of KMEFIDN (SEQ ID NO: 2).

### Claim 56 (depends on 55)

The polypeptide of claim 55, wherein said polypeptide includes the complete SRF polypeptide, but contains one of said mutations.

### Claim 57 (depends on 55)

The polypeptide of claim 55, wherein said polypeptide is 25, 30, 40, 50, 60 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 508 or 511 residues in length.

### Claim 58 (depends on 55)

The polypeptide of claim 55, wherein said polypeptide comprises the sequence SGAKPGKKTRGRVKIKMEFIDNKLRRYTTFSKRKTGIMKKAYELSTLT (SEQ ID NO: 1) and a mutation or mutations selected from an insertion, deletions or substitution in region of KMEFIDN (SEQ ID NO: 2).

### Claim 59 (depends on 55)

The polypeptide of claim 55, wherein the mutation is a substitution of residue 147 and/or 153 of SRF, deletion of residues 147 and/or 153 of SRF, and a one to three residue insertion adjacent to or within 2-3 residues of residues 147 and/or 153 of SRF.

### Claim 60 (depends on 55)

The polypeptide of claim 55, wherein the insertion is a triple alanine insertion.
